You’ve recently been diagnosed with metastatic cancer. You started the recommended first-line therapy, but it isn’t cutting it. There is another available treatment, but your hopes are crushed upon learning that you will have to wait at least three months before the life-extending medication can be produced for you and reach your location. All the
The deadly consequences of a shortage: The Pluvicto crisis leaves metastatic prostate cancer patients in limbo originally appeared in KevinMD.com.
